

## APC/Cyanine7 anti-human CD45RA Antibody

<b>Catalog# / Size</b>	304127 / 25 tests 304128 / 100 tests
<b>Clone</b>	HI100
<b>Regulatory Status</b>	RUO
<b>Workshop</b>	IV N906
<b>Other Names</b>	GP180, L-CA, LCA, LY5, T200, PTPRC
<b>Isotype</b>	Mouse IgG2b, κ
<b>Description</b>	CD45RA is a 205-220 kD single chain type I glycoprotein. It is an exon 4 splice variant of the tyrosine phosphatase CD45. The CD45RA isoform is expressed on resting/naïve T cells, medullary thymocytes, B cells and monocytes. CD45RA enhances both T cell receptor and B cell receptor signaling. CD45 non-covalently associates with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4. CD45 has also been reported to bind galectin-1. CD45 isoform expression can change in response to cytokines.

### Product Details

---

<b>Verified Reactivity</b>	Human
<b>Reported Reactivity</b>	Chimpanzee
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Mouse
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
<b>Preparation</b>	The antibody was purified by affinity chromatography and conjugated with APC/Cyanine7 under optimal conditions.
<b>Concentration</b>	Lot-specific (to obtain lot-specific concentration, please enter the lot number in our <a href="#">Concentration and Expiration Lookup</a> or <a href="#">Certificate of Analysis</a> online tools.)
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	Additional reported applications (for relevant formats of this clone) include: inhibition of CD45 functions <sup>2</sup> , immunohistochemical staining of frozen tissue sections <sup>3</sup> and formalin-fixed paraffin-embedded tissue sections <sup>4</sup> , and immunocytochemistry <sup>15,16</sup> .
<b>Additional Product Notes</b>	BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact <a href="#">Technical Service</a> if you have any questions.
<b>Application References</b>	<ol style="list-style-type: none"> <li>Knapp W, <i>et al.</i> 1989. Leucocyte Typing IV. Oxford University Press. New York.</li> <li>Yamada T, <i>et al.</i> 2002. <i>J. Biol. Chem.</i> 277:28830. (WB, Block)</li> <li>Weninger W, <i>et al.</i> 2003 <i>J. Immunol.</i> 170:4638. (IHC-F)</li> <li>Imanguli MM, <i>et al.</i> 2009. <i>Blood.</i> 113:3620 (IHC-P)</li> <li>Roque S, <i>et al.</i> 2007. <i>J. Immunol.</i> 178:8028. (FC) <a href="#">PubMed</a></li> <li>Smeltz RB. 2007. <i>J. Immunol.</i> 178:4786. (FC) <a href="#">PubMed</a></li> </ol>
<b>(PubMed link indicates BioLegend citation)</b>	

7. Palendira U, *et al.* 2008. *Blood* (FC) [PubMed](#)
8. Kuttruff S, *et al.* 2009. *Blood* 113:358. (FC) [PubMed](#)
9. Thakral D, *et al.* 2008. *J. Immunol.* 180:7431. (FC) [PubMed](#)
10. Alanio C, *et al.* 2010. *Blood* 115:3718. (FC) [PubMed](#)
11. Iannello A, *et al.* 2010. *J. Immunol.* 184:114. (FC) [PubMed](#)
12. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
13. Guereau-de-Arellan M, *et al.* 2011. *Brain.* 134:3578. [PubMed](#)
14. Canque B, *et al.* 2000. *Blood* 96:3748. (ICC)
15. Imanuli MM, *et al.* 2009. *Blood* 13:3620. (ICC)
16. Stoeckius M, *et al.* 2017. *Nat. Methods.* 14:865. (PG)
17. Peterson VM, *et al.* 2017. *Nat. Biotechnol.* 35:936. (PG)

## Product Citations

1. Liu Y, *et al.* 2022. *Signal Transduct Target Ther.* 7:347. [PubMed](#)
2. Shoda H, *et al.* 2017. *Arthritis Research & Therapy* . 10.1186/s13075-017-1308-y. [PubMed](#)
3. Chagraoui J, *et al.* 2021. *Cell Stem Cell.* 28(1):48-62.e6. [PubMed](#)
4. Yamauchi T *et al.* 2018. *Cancer cell.* 33(3):386-400 . [PubMed](#)
5. Berres M, *et al.* 2014. *J Exp Med.* 211:669. [PubMed](#)
6. Ishizaka A, *et al.* 2016. *J Virol.* 90: 5665 - 5676. [PubMed](#)
7. Nagafuchi Y, *et al.* 2016. *Sci Rep.* 6:29338. [PubMed](#)
8. Ho T, *et al.* 2016. *Blood.* 128: 1671 - 1678. [PubMed](#)
9. Todd J, *et al.* 2016. *PLoS Med.* 13:e1002139. [PubMed](#)
10. Karlsson H, *et al.* 2015. *PLoS One.* 10: 0144787. [PubMed](#)
11. Qi Q, *et al.* 2016. *PLoS Pathog.* 12:e1005892. [PubMed](#)
12. Hu W, *et al.* 2021. *Vaccines* (Basel). 9:. [PubMed](#)
13. Ma X *et al.* 2019. *eLife.* 8 pii: e42426. [PubMed](#)
14. Xiao X, *et al.* 2019. *Cell Discov.* 5:2. [PubMed](#)
15. Björklund &, *et al.* 2016. *Nat Immunol.* 17:451-460. [PubMed](#)
16. Wilson AS, *et al.* 2022. *Nat Commun.* 13:528. [PubMed](#)
17. Masson J, *et al.* 2017. *PLoS One.* 10.1371/journal.pone.0183931. [PubMed](#)
18. Zheng S, *et al.* 2018. *Mol Syst Biol.* 14:e8041. [PubMed](#)
19. Bulgarelli J, *et al.* 2021. *Front Immunol.* 12:778459. [PubMed](#)
20. Wang X, *et al.* 2021. *Cell Discovery.* 7(1):60. [PubMed](#)
21. Jung JH, *et al.* 2021. *Nat Commun.* 12:4043. [PubMed](#)
22. Nakasone H, *et al.* 2021. *Commun Biol.* 4:1177. [PubMed](#)
23. Collins DR, *et al.* 2021. *Immunity.* 54:2372. [PubMed](#)
24. Nakachi S, *et al.* 2017. *Arthritis Research & Therapy* . 10.1186/s13075-017-1309-x. [PubMed](#)
25. Kim MY, *et al.* 2022. *Nat Commun.* 13:3296. [PubMed](#)
26. Chen Y, *et al.* 2020. *Cell.* 1496:183. [PubMed](#)
27. Keller B, *et al.* 2016. *J Exp Med.* 213: 1185 - 1199. [PubMed](#)
28. Beyer M, *et al.* 2016. *Nat Immunol.* 17:593-603. [PubMed](#)
29. Crippa S, *et al.* 2019. *J Clin Invest.* 129:1566. [PubMed](#)
30. Yamaguchi K, *et al.* 2018. *Cancer Sci.* 109:3032. [PubMed](#)
31. Tomellini E, *et al.* 2020. *Cell Reports.* 28(4):1063-1073.e5.. [PubMed](#)
32. Mann EH, *et al.* 2019. *J Immunol.* 202:684. [PubMed](#)

## RRID

AB\_10708419 (BioLegend Cat. No. 304127)  
 AB\_10708880 (BioLegend Cat. No. 304128)

## Antigen Details

---

<b>Structure</b>	Tyrosine phosphatases, type I transmembrane (exon 4 splicing of CD45 gene), 205-220 kD
<b>Distribution</b>	B cells, naïve T cells, monocytes
<b>Function</b>	Enhances TCR and BCR signaling
<b>Ligand/Receptor</b>	Galectin-1, CD2, CD3, CD4
<b>Cell Type</b>	B cells, Monocytes, T cells, Tregs
<b>Biology Area</b>	Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	1. Thomas M. 1989. <i>Annu. Rev. Immunol.</i> 7:339. 2. Trowbridge I, <i>et al.</i> 1994. <i>Annu. Rev. Immunol.</i> 12:85.
<b>Gene ID</b>	<a href="#">5788</a>


## Related Protocols

---

## Other Formats

APC anti-human CD45RA, Biotin anti-human CD45RA, FITC anti-human CD45RA, PE anti-human CD45RA, PE/Cyanine5 anti-human CD45RA, Purified anti-human CD45RA, Alexa Fluor® 488 anti-human CD45RA, Alexa Fluor® 647 anti-human CD45RA, Pacific Blue™ anti-human CD45RA, Alexa Fluor® 700 anti-human CD45RA, PerCP/Cyanine5.5 anti-human CD45RA, PE/Cyanine7 anti-human CD45RA, APC/Cyanine7 anti-human CD45RA, Brilliant Violet 421™ anti-human CD45RA, Brilliant Violet 570™ anti-human CD45RA, Brilliant Violet 605™ anti-human CD45RA, Brilliant Violet 650™ anti-human CD45RA, Brilliant Violet 711™ anti-human CD45RA, Brilliant Violet 785™ anti-human CD45RA, Brilliant Violet 510™ anti-human CD45RA, Purified anti-human CD45RA (Maxpar® Ready), PE/Dazzle™ 594 anti-human CD45RA, APC/Fire™ 750 anti-human CD45RA, PerCP anti-human CD45RA, TotalSeq™-A0063 anti-human CD45RA, Alexa Fluor® 594 anti-human CD45RA, TotalSeq™-B0063 anti-human CD45RA, TotalSeq™-C0063 anti-human CD45RA, Brilliant Violet 750™ anti-human CD45RA, Spark NIR™ 685 anti-human CD45RA, PE/Fire™ 640 anti-human CD45RA, PE/Fire™ 700 anti-human CD45RA Antibody, Spark YG™ 581 anti-human CD45RA, TotalSeq™-D0063 anti-human CD45RA, Spark Violet™ 423 anti-human CD45RA, GMP FITC anti-human CD45RA, Spark UV™ 387 anti-human CD45RA

## Product Data



Human peripheral blood lymphocytes were stained CD45RA (clone HI100) APC/Cyanine7 (filled histogram) or mouse IgG2b, ? APC/Cyanine7 isotype control (open histogram).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587